Noopept vs Semax: What the Research Shows

Research use only. Everything below describes published preclinical literature. Noopept and Semax are supplied strictly as laboratory reagents for in vitro and analytical work. They are not for human or veterinary use, and not for diagnostic or therapeutic application.

Noopept and Semax come up together often in the nootropic research literature, and it is easy to see why. Both originated in Russian pharmacology institutes, both are short peptide or peptide-like molecules, and both have been studied in rodent cognition and neuroprotection models. Beyond that surface similarity, though, they are structurally and mechanistically quite different compounds. This article compares what the preclinical record actually says about each one, and what the practical differences mean for a laboratory that handles both.

What is Noopept and what is Semax?

Noopept (also catalogued as GVS-111, and chemically as N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic proline-containing dipeptide. It was designed at the Institute of Pharmacology of the Russian Academy of Medical Sciences using a peptide-design strategy that set out to mimic the pharmacophore of piracetam in a short-peptide scaffold. Reviews of the compound describe it as active at dose levels roughly three orders of magnitude below piracetam in the rodent models used, and note that it remains active after oral administration in animals, which is unusual for a peptide-based structure.

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is a synthetic analogue of the adrenocorticotropic hormone fragment ACTH(4-10), extended at the C-terminus with a Pro-Gly-Pro tripeptide that was added to slow enzymatic degradation. Unlike its parent fragment, Semax is described in the literature as lacking the corticotropic hormonal activity of full-length ACTH, which is the reason it became a subject of neuropeptide research rather than endocrine research.

So the first difference is basic: Noopept is a small dipeptide ester with a phenylacetyl group, and Semax is a genuine seven-residue peptide derived from a hormone fragment. That difference drives almost everything else, from mechanism to handling.

Where they sit in the research literature

Both compounds have a preclinical body of work built mostly on rodent models and cell culture. The reported research areas below are descriptions of what investigators have measured in animals and in vitro. They are not claims about outcomes in people.

Reported preclinical areas for Noopept

• Memory consolidation and retrieval endpoints in rodent avoidance and maze paradigms, where reviews describe a broader mnemotropic profile than piracetam, which acted mainly on early acquisition stages.
• Neuroprotective endpoints in models of experimental brain ischemia, and in neuronal culture models of injury.
• Antioxidant activity, anti-inflammatory readouts, and attenuation of calcium and glutamate excitotoxicity in cellular assays.
• An anxiolytic-type signature in rodent behavioural batteries, reported alongside the cognitive endpoints.
• Protein aggregation chemistry. One biophysics study examined how Noopept interacts with alpha-synuclein amyloid oligomers in vitro and reported that it promoted their sequestration into larger fibrillar aggregates, with reduced cytotoxicity toward SH-SY5Y neuroblastoma cells in the assay.

Reported preclinical areas for Semax

• Neurotrophin gene and protein expression. Work in Wistar rats reported increases in BDNF messenger RNA and protein, and in trkB receptor expression and phosphorylation, in the hippocampus following a single intranasal application.
• Region-specific transcriptional effects. The same line of work described rapid and region-dependent changes in Ngf and Bdnf expression across hippocampus, brainstem, cerebellum and frontal cortex, rather than a uniform whole-brain response.
• Behavioural endpoints in conditioned avoidance paradigms in rats, reported in parallel with the hippocampal BDNF and trkB measurements.
• Neuroprotection models, including ischemia paradigms, where the peptide has been examined in the Russian literature.
• Melanocortin and ACTH fragment pharmacology more broadly, since Semax sits in the same structural family as other ACTH(4-10) derived research peptides.

Chemistry and notes at a glance

Noopept. Chemical name N-phenylacetyl-L-prolylglycine ethyl ester. Molecular formula C17H22N2O4, molecular weight approximately 318.4 g/mol. A dipeptide ethyl ester, so it carries a hydrolysable ester bond. Typically supplied as a white crystalline powder or in capsule format for analytical work. Sparingly soluble in water, more readily handled in ethanol or DMSO for stock preparation depending on the assay.

Semax. Sequence Met-Glu-His-Phe-Pro-Gly-Pro. Molecular formula C37H51N9O10S, molecular weight approximately 813.9 g/mol. A true heptapeptide, usually supplied as a lyophilized powder. Water soluble and normally reconstituted in bacteriostatic water or a comparable aqueous solvent. Contains methionine, which is oxidation sensitive, and histidine, which makes the peptide somewhat pH sensitive in solution.

Noopept vs Semax: the practical differences for a research setting

Molecular class. Noopept is a small-molecule-like dipeptide ester. Semax is a peptide of nearly 814 daltons. In practice this means Noopept behaves more like a conventional organic reagent in the lab, while Semax needs peptide handling discipline.

Mechanistic emphasis in the literature. The Noopept record leans toward antioxidant, anti-excitotoxic and aggregation-modulating chemistry, plus a piracetam-derived design lineage. The Semax record leans heavily toward neurotrophic signalling, specifically the BDNF and trkB axis, and toward gene expression changes measured by real-time PCR.

Format. Noopept is commonly stocked in capsule form for weight-standardised analytical work. Semax is a lyophilized peptide requiring reconstitution before use. If you are comparing form factors more generally, see our note on bacteriostatic water vs acetic acid for peptide reconstitution.

Stability. The dry dipeptide is comparatively robust. The heptapeptide is more sensitive once in solution, both to oxidation of its methionine residue and to freeze-thaw cycling.

For single-compound background, we have separate deep dives on Noopept and on Semax, and a different pairing in Semax vs Selank. The wider category sits in our nootropic and racetam research compounds overview.

Why the "research use only" label matters

Neither compound is an approved medicine in the European Union. Noopept has been marketed as a prescription product in Russia and in some CIS countries, and Semax likewise holds Russian registrations, but neither has a marketing authorisation from the European Medicines Agency and neither is FDA approved. Under EU law, a research chemical stays a chemical reagent under REACH only while it is supplied and described as one. The moment it is presented with a therapeutic claim or with instructions for human use, it falls under medicinal products legislation, which is a different and much stricter regime.

That is the whole reason the framing on this page is what it is. There is no dosing information here, no administration guidance, and no suggestion that anything observed in a rat hippocampus transfers to a person. Rodent and cell culture findings are hypothesis-generating. They are the starting point of a development pathway, not the end of one.

A note on regulatory status worth stating plainly: neither Noopept nor Semax appears on the WADA Prohibited List as a named substance at the time of writing, but both are unapproved investigational compounds in the EU, and unapproved substances can still fall under the catch-all S0 category in sport. Anyone working in a regulated environment should verify current status independently.

Handling and storage for researchers

These are laboratory reagent handling notes, not use instructions.

• Dry storage. Keep both compounds sealed, dry and protected from light. Lyophilized Semax is best held at -20 degrees Celsius for long-term storage. Noopept powder or capsules are generally stable at cool room temperature in a desiccated container, though refrigeration extends shelf life.
• Reconstitution. Semax dissolves readily in aqueous solvent. Add solvent slowly down the vial wall rather than directly onto the cake, and swirl instead of shaking to avoid shear and foaming.
• Solution storage. Reconstituted peptide should be refrigerated at 2 to 8 degrees Celsius and used within a short window. For longer holds, aliquot before freezing so you never freeze-thaw the same vial twice.
• Oxidation. The methionine residue in Semax is the vulnerable point. Minimise headspace, keep solutions cold, and avoid prolonged exposure to light and air.
• Documentation. Record lot number, reconstitution date, solvent, and concentration on every aliquot. Cross-check the identity and purity figures against the supplied certificate of analysis. Our guide to peptide purity and the COA covers what those numbers mean, and the peptide storage and stability guide goes deeper on degradation pathways.
• PPE and labelling. Standard laboratory practice applies. Gloves, eye protection, and clear "Research Use Only, not for human or veterinary use" labelling on every container.

Frequently asked questions

Are Noopept and Semax the same class of compound?

No. Noopept is a synthetic dipeptide ethyl ester designed to mimic a piracetam-type pharmacophore in a short-peptide scaffold. Semax is a seven-residue peptide analogue of the ACTH(4-10) hormone fragment. They share a peptide character and a common research field, but they are structurally distinct and the preclinical literature emphasises different mechanisms for each.

Is either Noopept or Semax an approved drug?

Not in the European Union or the United States. Both hold registrations in Russia and some neighbouring countries, but neither has EMA marketing authorisation and neither is FDA approved. In the EU they are supplied only as research chemicals for laboratory use.

Is Noopept or Semax legal to buy for research in the EU?

Both are legal to supply and purchase within the EU as chemical reagents for laboratory research, provided they are sold, labelled and described as research use only, with no human or veterinary use implied and no therapeutic claims attached. National rules vary, so buyers are responsible for confirming the position in their own country. Pure Chems supplies both strictly on a research use only basis.

Which one has the larger published literature?

Both have modest literatures compared to mainstream pharmacological agents, and a significant share of each is published in Russian-language journals. Semax has a relatively well-defined molecular narrative around BDNF and trkB expression in rat hippocampus. Noopept has a broader spread across ischemia models, antioxidant chemistry, and protein aggregation biophysics. Neither has the volume of large independent replication that would be expected of a well-established compound.

Do the storage requirements differ?

Yes, meaningfully. Semax is a lyophilized peptide with an oxidation-sensitive methionine residue and needs cold storage, careful reconstitution, and aliquoting before freezing. Noopept in powder or capsule form is a more robust dry solid and tolerates ordinary cool, dry, dark storage, though refrigeration still helps.

Key takeaways

• Noopept is a synthetic proline-containing dipeptide ester with a piracetam-derived design lineage. Semax is a heptapeptide analogue of the ACTH(4-10) fragment stabilised with a C-terminal Pro-Gly-Pro extension.
• The Noopept preclinical record centres on rodent memory endpoints, ischemia models, antioxidant and anti-excitotoxic chemistry, and in vitro work on amyloid oligomer behaviour.
• The Semax preclinical record centres on neurotrophin signalling, with reported increases in hippocampal BDNF and trkB expression in rats and region-specific transcriptional changes.
• Practically, Noopept handles like a conventional dry organic reagent while Semax requires peptide-grade handling, cold storage and aliquoting.
• Neither compound is approved in the EU. Both are supplied for laboratory research only, with no human or veterinary use.

Where to source research-grade material

Pure Chems supplies both compounds to EU researchers with a certificate of analysis: Noopept 20mg x 60 capsules and Semax 40mg. Both are sold strictly for research use only.

References

References sourced via PubMed.

1. Ostrovskaya RU, Gudasheva TA, Voronina TA, Seredenin SB. The original novel nootropic and neuroprotective agent noopept. Eksperimental'naia i Klinicheskaia Farmakologiia. 2002;65(5):66-72. PubMed 12596521
2. Jia X, Gharibyan AL, Ohman A, Liu Y, Olofsson A, Morozova-Roche LA. Neuroprotective and nootropic drug noopept rescues alpha-synuclein amyloid cytotoxicity. Journal of Molecular Biology. 2011;414(5):699-712. doi:10.1016/j.jmb.2011.09.044 | PubMed 21986202
3. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108 | PubMed 16996037
4. Agapova TY, Agniullin YV, Shadrina MI, et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Neuroscience Letters. 2007;417(2):201-205. doi:10.1016/j.neulet.2007.02.042 | PubMed 17353092

Disclaimer: Research use only. Not for human or veterinary use. Not for diagnostic or therapeutic application. The content above summarises published preclinical literature for informational purposes and is not medical advice. Findings in cell culture and animal models do not establish safety or effect in humans. Researchers are responsible for compliance with all applicable national and EU regulations.